PT  - JOURNAL ARTICLE
AU  - Takenouchi, Toshiki
AU  - Iwasaki, Yuka W.
AU  - Harada, Sei
AU  - Ishizu, Hirotsugu
AU  - Uwamino, Yoshifumi
AU  - Uno, Shunsuke
AU  - Osada, Asami
AU  - Hasegawa, Naoki
AU  - Murata, Mitsuru
AU  - Takebayashi, Toru
AU  - Fukunaga, Koichi
AU  - Saya, Hideyuki
AU  - Kitagawa, Yuko
AU  - Amagai, Masayuki
AU  - Siomi, Haruhiko
AU  - Kosaki, Kenjiro
AU  - ,
TI  - Clinical Utility of SARS-CoV-2 Whole Genome Sequencing in Deciphering Source of Infection
AID  - 10.1101/2020.05.21.20107599
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.21.20107599
4099  - http://medrxiv.org/content/early/2020/05/26/2020.05.21.20107599.short
4100  - http://medrxiv.org/content/early/2020/05/26/2020.05.21.20107599.full
AB  - The novel coronavirus disease (COVID-19) pandemic caused by SARS-CoV-2 is a major threat to humans. Recently, we encountered two seemingly separate COVID-19 clusters in a tertiary care medical center. Whole viral genome sequencing detected the haplotype of the SARS-CoV-2 genome and the two clusters were successfully distinguished by the viral genome haplotype. Concurrently, there were nine COVID-19 patients clinically unlinked to clusters #1 or #2 that necessitated the determination of the source of infection. Such patients had similar haplotypes to those in cluster #2 but were devoid of two rare mutations characteristic to cluster #2. This suggested that these nine cases of “probable community infection” indeed had community infection and were not derived from cluster #2. Whole viral genome sequencing of SARS-CoV-2 is a powerful measure not only for monitoring the global trend of SARS-CoV-2 but also for identifying the source of infection of COVID-19 at a level of institution.Competing Interest StatementThe authors have declared no competing interest.Funding StatementInternal research fundAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Keio University School of Medicine Ethics Committee approved the present study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe uploaded the full nucleotide sequences of our cohort to the GISAID database (https://www.gisaid.org/). https://www.gisaid.org/